Estimating the fraction of progeny virions that must incorporate APOBEC3G for suppression of productive HIV-1 infection

Virology

Volumn 449, Issue , 2014, Pages 224-228

  Thangavelu, Pulari U ^a   Gupta, Vipul ^a   Dixit, Narendra M ^a  

^a INDIAN INSTITUTE OF SCIENCE   (India)

Author keywords

APOBEC; Extinction threshold; Hypermutation; Mathematical model; Stochastic simulations; Vif; Viral dynamics

Indexed keywords

APOLIPOPROTEIN B MESSENGER RNA EDITING ENZYME CATALYTIC POLYPEPTIDE 3G; VIF PROTEIN;

ARTICLE; GENE MUTATION; GENETIC RECOMBINATION; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; MOLECULAR DYNAMICS; MOLECULAR EVOLUTION; NONHUMAN; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROGENY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; QUANTITATIVE ANALYSIS; SIMULATION; SPECIES DIVERSITY; STOP CODON; UPREGULATION; VIRION;

HUMAN IMMUNODEFICIENCY VIRUS 1;

APOBEC; EXTINCTION THRESHOLD; HYPERMUTATION; MATHEMATICAL MODEL; STOCHASTIC SIMULATIONS; VIF; VIRAL DYNAMICS;

CYTIDINE DEAMINASE; DOWN-REGULATION; HIV INFECTIONS; HIV-1; HUMANS; MODELS, THEORETICAL; PROTEIN BINDING; VIF GENE PRODUCTS, HUMAN IMMUNODEFICIENCY VIRUS; VIRION; VIRUS REPLICATION;

EID: 84890061130     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2013.11.026     Document Type: Article

References (44)

1. Armitage A.E., Deforche K., Chang C.-h., Wee E., Kramer B., Welch J.J., Gerstoft J., Fugger L., McMichael A., Rambaut A., Iversen A.K.N. APOBEC3G-induced hypermutation of human immunodeficiency virus type-1 is typically a discrete "all or nothing" phenomenon. PLoS Genet 2012, 8(3):e1002550.
2. Balagam R., Singh V., Sagi A.R., Dixit N.M. Taking multiple infections of cells and recombination into account leads to small within-host effective-population-size estimates of HIV-1. PLoS ONE 2011, 6(1):e14531.
3. Berkhout B., de Ronde A. APOBEC3G versus reverse transcriptase in the generation of HIV-1 drug-resistance mutations. AIDS 2004, 18(13):1861-1863.
4. Browne E.P., Allers C., Landau N.R. Restriction of HIV-1 by APOBEC3G is cytidine deaminase-dependent. Virology 2009, 387(2):313-321.
5. Cen S., Peng Z.-G., Li X.-Y., Li Z.-R., Ma J., Wang Y.-M., Fan B., You X.-F., Wang Y.-P., Liu F., Shao R.-G., Zhao L.-X., Yu L., Jiang J.-D. Small molecular compounds inhibit HIV-1 replication through specifically stabilizing APOBEC3G. J. Biol. Chem. 2010, 285(22):16546-16552.
6. Compton Alex A., Hirsch V.M., Emerman M. The host restriction factor APOBEC3G and retroviral Vif protein coevolve due to ongoing genetic conflict. Cell Host Microbe 2012, 11(1):91-98.
7. Dapp M.J., Holtz C.M., Mansky L.M. Concomitant lethal mutagenesis of human immunodeficiency virus type 1. J. Mol. Biol. 2012, 419:158-170.
8. Dapp M.J., Patterson S.E., Mansky L.M. Back to the future: revisiting HIV-1 lethal mutagenesis. Trends Microbiol. 2012, 21(2):56-62.
9. Ejima T., Hirota M., Mizukami T., Otsuka M., Fujita M. An anti-HIV-1 compound that increases steady-state expression of apoplipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G. Int. J. Mol. Med. 2011, 28:613-616.
10. Finzi D., Blankson J., Siliciano J.D., Margolick J.B., Chadwick K., Pierson T., Smith K., Lisziewicz J., Lori F., Flexner C., Quinn T.C., Chaisson R.E., Rosenberg E., Walker B., Gange S., Gallant J., Siliciano R.F. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 1999, 5(5):512-517.
11. Harris R.S. Enhancing immunity to HIV through APOBEC. Nat. Biotech. 2008, 26(10):1089-1090.
12. Harris R.S., Liddament M.T. Retroviral restriction by APOBEC proteins. Nat. Rev. Immunol. 2004, 4(11):868-877.
13. Hosseini I., Mac Gabhann F. Multi-scale modeling of HIV infection in vitro and APOBEC3G-based anti-retroviral therapy. PLoS Comput. Biol. 2012, 8(2):e1002371.
14. Jern P., Russell R.A., Pathak V.K., Coffin J.M. Likely role of APOBEC3G-mediated G-to-A mutations in HIV-1 evolution and drug resistance. PLoS Pathog. 2009, 5(4):e1000367.
15. Josefsson L., King M.S., Makitalo B., Brannstrom J., Shao W., Maldarelli F., Kearney M.F., Hu W.-S., Chen J., Gaines H., Mellors J.W., Albert J., Coffin J.M., Palmer S.E. Majority of CD4+ T cells from peripheral blood of HIV-1-infected individuals contain only one HIV DNA molecule. Proc. Natl. Acad. Sci. USA 2011, 108(27):11199-11204.
16. Keele B.F., Giorgi E.E., Salazar-Gonzalez J.F., Decker J.M., Pham K.T., Salazar M.G., Sun C.X., Grayson T., Wang S.Y., Li H., Wei X.P., Jiang C.L., Kirchherr J.L., Gao F., Anderson J.A., Ping L.H., Swanstrom R., Tomaras G.D., Blattner W.A., Goepfert P.A., Kilby J.M., Saag M.S., Delwart E.L., Busch M.P., Cohen M.S., Montefiori D.C., Haynes B.F., Gaschen B., Athreya G.S., Lee H.Y., Wood N., Seoighe C., Perelson A.S., Bhattacharya T., Korber B.T., Hahn B.H., Shaw G.M. Identification and characterisation of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl. Acad. Sci. USA 2008, 105(21):7552-7557.
17. Kieffer T.L., Kwon P., Nettles R.E., Han Y., Ray S.C., Siliciano R.F. G-to-A hypermutation in protease and reverse transcriptase regions of human immunodeficiency virus type 1 residing in resting CD4+ T cells in vivo. J. Virol. 2005, 79(3):1975-1980.
18. Kijak G.H., Janini L.M., Tovanabutra S., Sanders-Buell E., Arroyo M.A., Robb M.L., Michael N.L., Birx D.L., McCutchan F.E. Variable contexts and levels of hypermutation in HIV-1 proviral genomes recovered from primary peripheral blood mononuclear cells. Virology 2008, 376(1):101-111.
19. Kim E.-Y., Bhattacharya T., Kunstman K., Swantek P., Koning F.A., Malim M.H., Wolinsky S.M. Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure. J. Virol. 2010, 84(19):10402-10405.
20. Land A.M., Ball T.B., Luo M., Pilon R., Sandstrom P., Embree J.E., Wachihi C., Kimani J., Plummer F.A. Human immunodeficiency virus (HIV) type 1 proviral hypermutation correlates with CD4 count in HIV-infected women from Kenya. J. Virol. 2008, 82(16):8172-8182.
21. Lauring A.S., Andino R. Quasispecies theory and the behavior of RNA viruses. PLoS Pathog. 2010, 6(7):e1001005.
22. Malim M.H. APOBEC proteins and intrinsic resistance to HIV-1 infection. Phil. Trans. Roy. Soc. B 2009, 364(1517):675-687.
23. Martin K.L., Johnson M., D'Aquila R.T. APOBEC3G complexes decrease human immunodeficiency virus type 1 production. J. Virol. 2011, 85(18):9314-9326.
24. Mulder L.C.F., Harari A., Simon V. Cytidine deamination induced HIV-1 drug resistance. Proc. Natl. Acad. Sci. USA 2008, 105(14):5501-5506.
25. Mullins J.I., Heath L., Hughes J.P., Kicha J., Styrchak S., Wong K.G., Rao U., Hansen A., Harris K.S., Laurent J.-P., Li D., Simpson J.H., Essigmann J.M., Loeb L.A., Parkins J. Mutation of HIV-1 genomes in a clinical population treated with the mutagenic nucleoside KP1461. PLoS ONE 2011, 6(1):e15135.
26. Nathans R., Cao H., Sharova N., Ali A., Sharkey M., Stranska R., Stevenson M., Rana T.M. Small-molecule inhibition of HIV-1 Vif. Nat. Biotech. 2008, 26(10):1187-1192.
27. Norman J.M., Mashiba M., McNamara L.A., Onafuwa-Nuga A., Chiari-Fort E., Shen W., Collins K.L. The antiviral factor APOBEC3G enhances the recognition of HIV-infected primary T cells by natural killer cells. Nat. Immunol. 2011, 12(10):975-983.
28. Nowak M.A., May R.M. Virus Dynamics: Mathematical Principles of Immunology and Virology 2000, Oxford University Press, New York.
29. Nowarski R., Britan-Rosich E., Shiloach T., Kotler M. Hypermutation by intersegmental transfer of APOBEC3G cytidine deaminase. Nat. Struct. Mol. Biol. 2008, 15(10):1059-1066.
30. Perelson A.S. Modeling viral and immune system dynamics. Nat. Rev. Immunol. 2002, 2(1):28-36.
31. Piantadosi A., Humes D., Chohan B., McClelland R.S., Overbaugh J. Analysis of the percentage of human immunodeficiency virus type 1 sequences that are hypermutated and markers of disease progression in a longitudinal cohort, including one individual with a partially defective vif. J. Virol. 2009, 83(16):7805-7814.
32. Pillai S., Wong J., Barbour J. Turning up the volume on mutational pressure: is more of a good thing always better? (A case study of HIV-1 Vif and APOBEC3). Retrovirology 2008, 5(1):26.
33. Ribeiro R.M., Qin L., Chavez L.L., Li D., Self S.G., Perelson A.S. Estimation of the initial viral growth rate and basic reproductive number during acute HIV-1 infection. J. Virol. 2010, 84(12):6096-6102.
34. Russell R., Moore M., Hu W.-S., Pathak V. APOBEC3G induces a hypermutation gradient: purifying selection at multiple steps during HIV-1 replication results in levels of G-to-A mutations that are high in DNA, intermediate in cellular viral RNA, and low in virion RNA. Retrovirology 2009, 6(1):16.
35. Sadler H.A., Stenglein M.D., Harris R.S., Mansky L.M. APOBEC3G contributes to HIV-1 variation through sublethal mutagenesis. J. Virol. 2010, 84(14):7396-7404.
36. Schultz A., Sopper S., Sauermann U., Meyerhans A., Suspene R. Stable multi-infection of splenocytes during SIV infection - the basis for continuous recombination. Retrovirology 2012, 9(1):31.
37. Smith H.C. APOBEC3G: a double agent in defense. Trends Biochem. Sci. 2011, 36(5):239-244.
38. Stafford M.A., Corey L., Cao Y., Daar E.S., Ho D.D., Perelson A.S. Modeling plasma virus concentration during primary HIV infection. J. Theor. Biol. 2000, 203(3):285-301.
39. Suspene R., Rusniok C., Vartanian J.-P., Wain-Hobson S. Twin gradients in APOBEC3 edited HIV-1 DNA reflect the dynamics of lentiviral replication. Nucleic Acids Res. 2006, 34(17):4677-4684.
40. Tripathi K., Balagam R., Vishnoi N.K., Dixit N.M. Stochastic simulations suggest that HIV-1 survives close to its error threshold. PLoS Comput. Biol. 2012, 8:e1002684.
41. Vijay N.N.V., Vasantika, Ajmani R., Perelson A.S., Dixit N.M. Recombination increases human immunodeficiency virus fitness, but not necessarily diversity. J. Gen. Virol. 2008, 89:1467-1477.
42. Wood N., Bhattacharya T., Keele B.F., Giorgi E., Liu M., Gaschen B., Daniels M., Ferrari G., Haynes B.F., McMichael A., Shaw G.M., Hahn B.H., Korber B., Seoighe C. HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog. 2009, 5(5):e1000414.
43. Xu H., Chertova E., Chen J., Ott D.E., Roser J.D., Hu W.-S., Pathak V.K. Stoichiometry of the antiviral protein APOBEC3G in HIV-1 virions. Virology 2007, 360(2):247-256.
44. Yu Q., Konig R., Pillai S., Chiles K., Kearney M., Palmer S., Richman D., Coffin J.M., Landau N.R. Single-strand specificity of APOBEC3G accounts for minus-strand deamination of the HIV genome. Nat. Struct. Mol. Biol. 2004, 11(5):435-442.